Regeneron CEO says fears over Eylea 'greatly exaggerated'

(Reuters) – Fears of the demise of blockbuster eye drug Eylea were “greatly exaggerated,” Regeneron Pharmaceuticals Inc’s chief executive said on Thursday, after the treatment and new eczema drug Dupixent powered the company’s fourth-quarter results.


Source: Reuters Health

Leave a Reply

Your email address will not be published. Required fields are marked *